The global market for Testosterone Replacement Therapy (TRT) is projected to reach US$3.4 billion by 2022, driven by the growing prevalence of hypogonadism supported by aging male population; rising awareness over the disease, its impact on quality of life and availability of therapies; improved diagnosis rates; growing preference for easy to use products; and expected approval of new generation drugs in the pipeline. In addition to aging male population, prevalence of male hypogonadism as a clinically significant syndrome is supported by the rise in hypothalamic, pituitary, testicular disorders. The market is also expected to benefit from developments in evidence-based diagnosis, effective treatment monitoring strategies and guidelines. The United States represents the largest market worldwide led by higher levels of patient literacy and awareness, launch and availability of several innovative TRT products, direct-to-customer advertising by manufacturers, favorable reimbursement policies, insurance coverage and ability to afford expensive medications. Asia-Pacific ranks as the fastest growing market with a CAGR of 19.8% through the analysis period driven by factors such as growing focus on men's health; epidemic spread of diabetes and the resulting development of low testosterone syndrome; improving healthcare infrastructure and availability of and access to therapies.
DOMAIN EXPERT ENGAGEMENTS
Number of executives repeatedly engaged by snail & email outreach*
POOL + OUTREACH
Interactions with Platform & by Email *
Unique # Participated *
Responses Validated *